About
Hemoglobin variants and thalassemias are two genetically distinct hemoglobin abnormalities. Thalassemias are characterized by a reduced synthesis of the normal globin chain due to gene deletions or mutations. The most common thalassemias are alpha- and beta-thalassemias. The hemoglobin variants are caused by amino acid substitutions in either globin chain. Globally, more than 1800 hemoglobin variants have been characterized(4,5) but only a few are widely common: Hb S, Hb C, Hb E and Hb D-Punjab.
Diagnosis
Hemoglobinopathies can present several clinical symptoms, from benign (mild microcytosis) to the most severe (sickle cell disease, Hb Bart’s hydrops fetalis, …) with multiple organ damage, requiring lifelong transfusions. Diagnosis and follow-up of hemoglobinopathies depend on the presence of abnormal hemoglobin fractions on electrophoresis profiles and the quantification of Hb A2.
Sebia's expertise
For more than 20 years, Sebia has developed a strong expertise in the field of hemoglobin disorders screening and is a recognised partner of choice for all laboratories and scientists involved in hemoglobinopathies.
In addition to hematological RBC parameters, the information on the type and quantification of hemoglobin given by the CE technique provides key information in the screening of hemoglobinopathies such as Thalassemia or Sickle Cell Disease(4,5).
Featured resources on Hemoglobin Disorders
See all resourcesPrecision of CAPILLARYS 2 for the Detection of Hemoglobin Variants Based on Their Migration Positions
In this report, we evaluated the use of the capillary electrophoresis (CE) migration position in the CAPILLARYS 2 CE instrument.
Further evaluation of the world health organization international reference reagent for Haemoglobin A2 measurement
This article assesses the performances of the different manufacturers and technologies (HPLC and CE) for Hb A2 measurement using both International Reference Reagent for HbA2 (WHO IRR 89/666) and analysis of three whole blood specimens over a range of HbA2, distributed to 56 laboratories located in 14 different countries.
Discover how the automation track integration boosted the high potential of CAPILLARYS 3
With this short video report, become aware of all the benefits of partnering with Sebia and integrate your capillary electrophoresis into the lab track automation.
CAPILLARYS 3 DBS – Introductory video
The perfect match for screening hemoglobin disorders in newborns
Newborn Screening for Sickle Cell Disease and other Haemoglobinopathies – MDPI – 2019
This special Issue related to newborn screening for Sickle Cell disease and other hemoglobinopathies tried to cover the most widely faced challenges in the field of newborn screening for SCD.
Hemoglobinopathy Testing: What are the Key Points a Lab Should Consider?
Educational Webinar Dr. Cornelia L. Harteveld from Leiden University Medical Center
Hemoglobinopathy Investigation – The Case for Capillary Electrophoresis
Educational Webinar with Jason EYRE
HYDRASYS 2 SCAN FOCUSING: Overview
Learn more about the HYDRASYS 2 SCAN FOCUSING for a fast and user-friendly gel electrophoresis processing.
How External Quality Assessment supports quality improvement in laboratory hemoglobinopathy diagnosis
Educational Webinar with Dr. Barbara De la Salle
Sebia receives U.S. FDA Clearance for the CAPILLARYS 3 DBS devices
The next generation instrument for screening hemoglobin disorders in newborns.
Upcoming events
See all eventsApr. 11, 2022 Dec. 21, 2024
IFCC Euromedlab 2021
Sebia booth: #121
Sebia Workshop: EduW22
Jun. 27, 2022 Jun. 29, 2022
IFCC Worldlab 2022
Sebia booth: #72
Sebia Workshop: EduW25
May. 22, 2023 May. 24, 2023
IFCC Euromedlab /WorldLab 2023
Sebia booth: #21
Sebia Workshop: EduW15
CAPILLARYS 3 OCTA
Evolution makes the difference.
CAPILLARYS 3 TERA MC
The power of up to 36 capillaries in one automated high volume workcell.
MINICAP FLEX-PIERCING
The compact and affordable automation of Capillary Electrophoresis.
CAPILLARYS 3 DBS
The high throughput solution for newborn hemoglobin disorders screening.
Hemoglobin disorders screening
The high-resolution method for hemoglobin disorders screening.
Newborn hemoglobin disorders screening
The perfect match for screening hemoglobin disorders in newborns.
(1) https://www.who.int/bulletin/volumes/86/6/06-036673.pdf?ua=1
(2) https://www.sciencedirect.com/science/article/pii/S2214109X13701505
(4) http://globin.cse.psu.edu/hbvar/menu.html
(5) https://www.tandfonline.com/doi/full/10.1080/17474086.2019.1656525
This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country.
Please contact your local Sebia representative. Information intended for healthcare professionals.
Carefully read the instructions in the reagent package inserts and instrument manuals.